IMVT - Immunovant, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
IMVT price evolution
IMVT
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $472.94 | $560 | $635.37 | $690.94 |
| Short term investments | ||||
| Net receivables | $1.88 | $2.42 | $5.34 | $1.03 |
| Inventory | ||||
| Total current assets | $507.37 | $589.05 | $665.77 | $710.78 |
| Long term investments | ||||
| Property, plant & equipment | $0.72 | $0.63 | $0.59 | $0.67 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.63 | $0.59 | $0.67 | |
| Total investments | ||||
| Total assets | $515.71 | $589.68 | $666.37 | $711.45 |
| Current liabilities | ||||
| Accounts payable | $20.73 | $11.04 | $7.17 | $3.91 |
| Deferred revenue | ||||
| Short long term debt | $0.07 | $0.14 | $0.31 | |
| Total current liabilities | $66.65 | $45.02 | $48.61 | $32.1 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | $0.07 | $0.14 | $0.31 | |
| Total liabilities | $66.65 | $45.02 | $48.61 | $32.1 |
| Shareholders' equity | ||||
| Retained earnings | -$1021.95 | -$912.83 | -$825.68 | -$750.36 |
| Other shareholder equity | $1.91 | $1.82 | $1.91 | -$0.6 |
| Total shareholder equity | $544.66 | $617.76 | $679.34 | |
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $635.37 | $376.53 | $493.82 | $400.15 |
| Short term investments | ||||
| Net receivables | $5.34 | $0.7 | $12.23 | $12.86 |
| Inventory | ||||
| Total current assets | $665.77 | $404.33 | $512.93 | $409.01 |
| Long term investments | ||||
| Property, plant & equipment | $0.59 | $1.5 | $2.63 | $3.48 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.59 | $1.5 | $2.63 | $3.48 |
| Total investments | ||||
| Total assets | $666.37 | $405.84 | $515.56 | $412.49 |
| Current liabilities | ||||
| Accounts payable | $7.17 | $1.7 | $18.8 | $2.43 |
| Deferred revenue | ||||
| Short long term debt | $0.14 | $1.17 | $1.15 | $1.18 |
| Total current liabilities | $48.61 | $43.3 | $44.52 | $18.77 |
| Long term debt | $0.05 | $1.22 | $2.24 | |
| Total noncurrent liabilities | $0.05 | $1.22 | $2.24 | |
| Total debt | $0.14 | $1.22 | $2.36 | $3.42 |
| Total liabilities | $48.61 | $43.34 | $45.74 | $21.01 |
| Shareholders' equity | ||||
| Retained earnings | -$825.68 | -$566.35 | -$355.39 | -$198.66 |
| Other shareholder equity | $1.91 | $0.85 | $0.4 | -$0.3 |
| Total shareholder equity | $617.76 | $362.49 | $469.82 | $391.48 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $75.47 | $66.06 | $48.34 | |
| Selling, general & administrative | $18.81 | $14.82 | $13.21 | |
| Total operating expenses | $115.74 | $94.28 | $80.88 | $61.55 |
| Operating income | -$94.28 | -$80.88 | -$61.55 | |
| Income from continuing operations | ||||
| EBIT | -$87.07 | -$75.09 | -$51.53 | |
| Income tax expense | $0.08 | $0.08 | $0.23 | -$0.11 |
| Interest expense | $6.07 | |||
| Net income | ||||
| Net income | -$109.12 | -$87.15 | -$75.32 | -$51.42 |
| Income (for common shares) | -$87.15 | -$75.32 | -$51.42 | |
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $212.93 | $160.26 | $101.81 | $68.6 |
| Selling, general & administrative | $57.28 | $48.02 | $54.23 | $39.51 |
| Total operating expenses | $282.71 | $218.53 | $156.03 | $108.12 |
| Operating income | -$282.71 | -$218.53 | -$156.03 | -$108.12 |
| Income from continuing operations | ||||
| EBIT | -$258.77 | -$210.95 | -$156.81 | -$107.79 |
| Income tax expense | $0.57 | $0.01 | -$0.08 | -$0.36 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$259.34 | -$210.96 | -$156.73 | -$107.43 |
| Income (for common shares) | -$259.34 | -$210.96 | -$156.73 | -$107.43 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$87.15 | -$75.32 | -$51.42 | |
| Operating activities | ||||
| Depreciation | $0.15 | $0.32 | $0.35 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $13.46 | $9.68 | $10.22 | |
| Total cash flows from operations | -$76.2 | -$59.7 | -$47.1 | |
| Investing activities | ||||
| Capital expenditures | -$0.18 | -$0.15 | -$0.13 | |
| Investments | ||||
| Total cash flows from investing | -$0.38 | -$0.18 | -$0.15 | -$0.13 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.69 | $1.54 | $475.86 | |
| Net borrowings | ||||
| Total cash flows from financing | $1.42 | $0.69 | $1.54 | $469.84 |
| Effect of exchange rate | $1.38 | $0.34 | $2.73 | -$1.61 |
| Change in cash and equivalents | -$162.42 | -$75.36 | -$55.57 | $421.01 |
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$259.34 | -$210.96 | -$156.73 | -$107.43 |
| Operating activities | ||||
| Depreciation | $1.36 | $1.32 | $1.23 | $1 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $41.12 | $32.3 | $34.24 | $18.82 |
| Total cash flows from operations | -$214.23 | -$188.19 | -$106.11 | -$83.33 |
| Investing activities | ||||
| Capital expenditures | -$0.36 | -$0.2 | -$0.25 | -$0.21 |
| Investments | ||||
| Total cash flows from investing | -$0.36 | -$0.2 | -$0.25 | -$0.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $478.44 | $71.16 | $0.13 | $387.54 |
| Net borrowings | -$3.19 | |||
| Total cash flows from financing | $472.43 | $70.89 | $200.13 | $383.11 |
| Effect of exchange rate | $0.99 | $0.22 | -$0.09 | |
| Change in cash and equivalents | $258.83 | -$117.28 | $93.67 | $299.57 |
News
Fundamentals
| Market cap | $2.11B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 146.57M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$323.01M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -6.53 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 3.23 |
| EPS | -$2.20 |
|---|---|
| ROA | -52.03% |
| ROE | N/A |
| Debt/Equity | 0.08 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.61 |
| Quick ratio | N/A |